Brr – It’s time to start thinking about the winter respiratory season
By Alison Adduono, Director of Marketing Communications
A forecast from the US Centers for Disease Control and Prevention indicates this respiratory disease season will once again be similar to last year, which saw hospital beds fuller than during the pandemic and pre-pandemic years. In general, the typical respiratory season occurs between early fall and spring, with peaks between December and February. COVID-19 will accompany the usual suspects such as colds, flu, RSV and strep. It is no secret that as people begin to gather indoors to escape the chilly weather and gather for Thanksgiving and other holiday celebrations, the SARS-CoV-2 virus will spread more easily. With people stopping many of their COVID-19 precautions (i.e., masking, social distancing, etc.) and reduced vaccination rates, the CDC’s forecast seems likely. While you may not want to think about it, this is the exact time your facility should prepare for it.
Not performing as many COVID-19 tests as in the past, you may not be aware the Nucleic Acid Amplification Test (NAAT) you may currently be using is no longer available for purchase. On April 11, 2023, Thermo Fisher Scientific announced it would discontinue the manufacturing of the Thermo Fisher Accula™ line of products. What does that mean for you now? You are in need of the perfect replacement for your COVID-19 testing… and Anavasi Diagnostics has your solution!
Photo Credit: iStock by Getty Images
The AscencioDx COVID-19 Test and Molecular Detector is FDA EUA authorized for use in Point of Care settings and is manufactured by Anavasi Diagnostics, headquartered in Redmond, WA. Like Accula, the AscencioDx is a NAAT producing highly accurate molecular test results.
Key Benefits:
Rapid Results: Providing positive test results in as little as 20 minutes.
Compact Size: This reusable detector is portable and does not monopolize lab counter space.
Easy and Convenient: This CLIA-waived system is incredibly user-friendly and does not require extensive training, making it a suitable choice for all healthcare settings. The transition from your current or previous COVID-19 testing platform is easy.
Efficient Reporting: Our dynamic QR code scanning feature allows for effortless transmission of test results to the secure cloud based Anavasi Detector Portal. Capturing, managing, and sharing test results just became much easier.
Brushing Up
Now is the best time to select your new COVID-19 NAAT, place it in your point-of-care operation, and complete staff training. Anavasi offers a unique onboarding experience for all customers. Not only will we provide you with personalized training, but we also offer a great package of resources for you including PowerPoint materials, training videos, and a certification quiz -- everything you need to get your team trained.
Contact our sales team today for more information at sales@anavasidx.com or call 888-262-8274.
Resources:
Where Speed, Efficiency, & Accuracy Align
The AscencioDx® Covid-19 Test and The AscencioDx® Molecular Detector have not been FDA cleared or approved, but have been authorized for emergency use by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.